cas 1505515-80-9|| where to buy tert-Butyl N-[(1R)-1-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethyl]carbamate

Nom du produit:tert-Butyl N-[(1R)-1-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethyl]carbamate

IUPAC Name:tert-butyl N-[(2R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]propan-2-yl]carbamate

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1505515-80-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1505515-80-9; Formule moléculaire:C20H32BNO5; Point de fusion:-; Code SMILES:CC1(C)OB(OC1(C)C)C2=CC=C(OC[C@H](NC(OC(C)(C)C)=O)C)C=C2; Densité:1.07±0.1 g/cm3

: Numéro de catalogue:CM1079407; Poids moléculaire:377.29; Point d'ébullition:493.5±30.0 °C; N° Mdl:; Stockage:

: Boronic Acids and Esters; Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).; Boronic Acid For Sale; Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

: Taletrectinib; Recently, Nuvation Bio announced positive pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies at the European Society for Medical Oncology (ESMO). Analysis showed that its small molecule taletrectinib, a new highly selective ROS1/NTRK kinase inhibitor, can cross the patient's blood-brain barrier to treat brain metastases, and nearly 90% of patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who received treatment had tumor shrinkage. In patients who had never been treated with tyrosine kinase inhibitors (TKIs), disease remission was sustained for nearly 4 years. Nuvation Bio plans to submit a new drug application (NDA) for the drug to the FDA in the fourth quarter of this year.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.